AI Summary & Key Takeaways
AI InsightInthe treatment group, mean basilar artery vasospasm index and mean basilar artery wallthickness were found to be significantly smaller than those of the SAH group, while meanbasilar artery cross-sectional luminal area in the treatment group was insignificantly greaterthan that of the SAH group.Conclusions: These findings revealed that intraperitoneal zoledronic acid administrationattenuated vasospastic changes such as increased vasospasm index and arterial wall thicknessin an experimental rat model of SAH.
📌 3 Key Takeaways
Abstract
Background: Early brain injury and cerebral vasospasm are major factors determiningoutcome for patients who experience subarachnoid hemorrhage (SAH). This study wasperformed to investigate the potential therapeutic effects of zoledronic acid on cerebralvasospasm in an experimental SAH model.Methods: Fifteen male Sprague Dawley rats were assigned randomly to one of three groups.Animals in Group I were subjected to sham operation and received no treatment after theprocedure (sham group, n=5). Animals in Group II were subjected to SAH and received notreatment after SAH induction (SAH group, n=5). Animals in Group III were subjected toSAH and received 0.1 mg/kg intraperitoneal zoledronic acid injection 2 hours after SAHinduction (treatment group, n=5). Animals were euthanized 48 hours after the surgicalprocedures. Neurological deficit grading, basilar artery vasospasm indices, arterial wallthicknesses, and cross-sectional luminal areas were evaluated. Data were statisticallycompared by Kruskal-Wallis and Mann-Whitney U tests.Results: The treatment group showed a better functional neurological amelioration incomparison to SAH group. However, the difference failed to reach statistical significance. Inthe treatment group, mean basilar artery vasospasm index and mean basilar artery wallthickness were found to be significantly smaller than those of the SAH group, while meanbasilar artery cross-sectional luminal area in the treatment group was insignificantly greaterthan that of the SAH group.Conclusions: These findings revealed that intraperitoneal zoledronic acid administrationattenuated vasospastic changes such as increased vasospasm index and arterial wall thicknessin an experimental rat model of SAH.
Özet
Amaç: Subaraknoid kanamalı (SAK) hastalarda sonucu belirleyen major faktörler erkenbeyin hasarı ve serebral vazospazmdır. Bu çalışma zoledronik asidin deneysel SAK modeliyleoluşturulmuş serebral vazospazm üzerine potansiyel tedavi edici etkisini araştırmak amacıylagerçekleştirilmiştir.Metod: Onbeş adet erkek Sprague Dawley rat rastlantısal olarak üç gruba ayrıldı. Grup I'dekiratlara sham operasyonu yapıldı ve işlem sonrası bir tedavi verilmedi (sham grubu,n=5). GrupII'deki ratlara SAK oluşturuldu ve işlem sonrası tedavi verilmedi (SAK grubu, n=5). GrupIII'deki ratlara SAK oluşturuldu ve 2 saat sonra 0.1 mg/kg intraperitoneal zoledronik asidverildi (tedavi grubu, n=5). Ratlar cerrahi işlemler tamamlandıktan 48 saat sonra sakrifiyeedildi. Nörolojik defisit dereceleri, baziller arter vazospazm indeksi, arterial duvar kalınlığı velumen kesit alanları değerlendirildi. Veriler istatistiksel olarak Kruskal-Wallis ve MannWhitney U testleri kullanılarak karşılaştırıldı.Bulgular: Tedavi grubunda ortalama baziller arter vazospazm indeksi ve ortalama arter duvarkalınlığı SAK grubuna göre istatistiksel anlamlı olarak daha az bulundu. Tedavi grubu SAKgrubuna göre istatistiksel olarak anlamlı olmamakla birlikte daha iyi bir fonksiyonel nörolojikiyileşme gösterdi ve baziller arter kesit alanı daha genişti.Sonuç: Bu bulgular ratlarda deneysel SAK modelinde intraperitoneal zoledronik asiduygulamasının vazospazm indeksi ve arterial duvar kalınlığı gibi vazospastik değişiklikleriiyileştirdiğini göstermektedir.